Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 205

Sort by

Sort Order Select

Journal Articles

Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

Andrew H. Lipsky, Brian T. Hill, Allison Winter, Spencer Henick Bachow, Aaron D. Viny, Todd L. Rosenblat, Joseph Jurcic, Nicole Lamanna

Blood (2023) 142 (Supplement 1): 3274.

https://doi.org/10.1182/blood-2023-189718

Published: 2023

Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett

Blood (2023) 142 (Supplement 1): 437.

https://doi.org/10.1182/blood-2023-173742

Published: 2023

Journal Articles

Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy

Fateeha Furqan, Katelin Baird, Merve Kacar, Annika S Surapaneni, Ulrich Kemmo Tsafack, Aniko Szabo, Jakub Svoboda, Brian T. Hill, Jason T. Romancik, Nirav N. Shah

Blood (2023) 142 (Supplement 1): 4486.

https://doi.org/10.1182/blood-2023-186703

Published: 2023

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Blood (2023) 142 (Supplement 1): 6938.

https://doi.org/10.1182/blood-2023-178526

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Safety Results of a Phase I Study of Zandelisib + R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

Deepa Jagadeesh, Paolo Caimi, Allison Winter, Wei Wei, Brad Pohlman, Christopher D'Andrea, Emily Rhoades, Robert M. Dean, Brian T. Hill

Blood (2023) 142 (Supplement 1): 6233.

https://doi.org/10.1182/blood-2023-191345

Published: 2023

Journal Articles

The Relapse-to-Therapy Interval in Relapsed or Refractory Diffuse Large B Cell Lymphoma Is Associated with Clinical Outcomes

Paolo F. Caimi, Christine Auberle, Krishna Goparaju, Molly Megan Gallogly, Firas Baidoun, Amanda F Cashen, Brian T. Hill

Blood (2023) 142 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2023-181274

Published: 2023

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Journal Articles

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Andre Goy, Caron A. Jacobson, Ian W. Flinn, Brian T. Hill, Wen-Kai Weng, Luke Mountjoy, Oluwole Olalekan, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Michael L. Wang

Blood (2023) 142 (Supplement 1): 106.

https://doi.org/10.1182/blood-2023-174273

Published: 2023

Journal Articles

Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy

Merve Kacar, Robert M. Dean, Allison Winter, Brad Pohlman, Deepa Jagadeesh, Brian T. Hill, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 6198.

https://doi.org/10.1182/blood-2023-190885

Published: 2023

Journal Articles

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Blood (2023) 142 (Supplement 1): 380.

https://doi.org/10.1182/blood-2023-189505

Published: 2023

Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2023) 142 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2023-179868

Published: 2023

Journal Articles

Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy

Jonathan Bakos, Silvia Escribano Serrat, Yazeed Sawalha, Alison Moskowitz, Anna Crawford, Taylor R. Brooks, Brian T. Hill, Ayo S Falade, Reid W. Merryman, Manali Kamdar, Andrew Ip, Gunjan L. Shah, Arash Velayati, McKenzie Sorrell, James A Davis, Irl Brian Greenwell, Ann LaCasce, Brian Hess

Blood (2023) 142 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2023-178740

Published: 2023

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2023-173943

Published: 2023

Journal Articles

Analytical and Clinical Validation of Duoseq, a Novel Assay for Rapid, on-Site Clinical DNA and RNA Sequencing of Hematologic Malignancies

Eric D. Hsi, Magdalena Czader, Brian T. Hill, Elizabeth Thacker, Lin Wang, Christopher Giauque, Andrea Vrydaghs, Matt Sperling, Jordan Bouldin, Robert Erno, Lanie Happ, Clayton Parker, Cassandra L. Love, Jennifer Shingleton, Sandeep Dave

Blood (2023) 142 (Supplement 1): 3670.

https://doi.org/10.1182/blood-2023-189030

Published: 2023

Journal Articles

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis S. Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Matt Kalaycio, Claudio Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, Paolo Caimi

Blood (2023) 142 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2023-188712

Published: 2023

Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Blood (2023) 142 (Supplement 1): 1908.

https://doi.org/10.1182/blood-2023-179198

Published: 2023

NARROW

Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Safety Results of a Phase I Study of Zandelisib + R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

The Relapse-to-Therapy Interval in Relapsed or Refractory Diffuse Large B Cell Lymphoma Is Associated with Clinical Outcomes

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Analytical and Clinical Validation of Duoseq, a Novel Assay for Rapid, on-Site Clinical DNA and RNA Sequencing of Hematologic Malignancies

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only